What is Inimmune?
Inimmune is a clinical-stage biotech company dedicated to discovering and developing innovative immunotherapies for cancer, allergies, autoimmunity, and vaccines. Their pipeline includes clinical-stage Toll-like receptor (TLR) agonists and various pre-clinical programs aimed at enhancing vaccine adjuvants. The company collaborates with leading universities and biotech firms to advance their research and development efforts. Inimmune's mission is to harness the immune system to improve human health through novel therapeutic solutions.
How much funding has Inimmune raised?
Inimmune has raised a total of $22M across 1 funding round:
Series A
$22M
Series A (2020): $22M with participation from Two Bears Capital
Key Investors in Inimmune
Two Bears Capital
Two Bears Capital is an investor in Inimmune's Series A funding round. Further details on their investment focus are not publicly available.
What's next for Inimmune?
With a substantial funding base and a clear strategic direction, Inimmune is poised for significant advancements in its therapeutic pipeline. The company's focus on TLR agonists and vaccine adjuvants positions it at the forefront of immunotherapy innovation. Future developments will likely involve progressing existing clinical-stage assets through further trials, expanding pre-clinical research into new indications, and potentially forging new strategic partnerships to leverage its platform technology. The recent major strategic investment signals a commitment to scaling operations and accelerating the translation of its research into tangible health benefits, reinforcing Inimmune's trajectory as a key player in the biopharmaceutical sector.
See full Inimmune company page
